Morgen Eric 4

What Happened

• Eric Morgen, Chief Operating Officer of BioAge Labs, received two derivative awards on February 17, 2026: 110,000 and 12,500 shares (total 122,500). The filing lists a price of $0.00 and classifies the transactions as awards/grants (code A), indicating these are equity compensation awards (derivative securities), not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (appears to be filed within the typical 2-business-day window).
• Award amounts: 110,000 and 12,500 derivative shares (total 122,500).
• Price shown: $0.00 in the filing (common for certain option/RSU award disclosures; these are reported as derivative awards).
• Vesting: Footnotes state each award vests 1/48th monthly, with the first tranche vested on Feb 1, 2026, and monthly thereafter, subject to continued service.
• Spouse note: filing includes a footnote that one option is directly held by the reporting person’s spouse.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• No sale/exercise reported: these are grants, not exercises or sales.

Context

• These awards are compensation-related equity grants that vest over four years; they are not immediate cash transactions or open-market buys/sells. Such grants are routine for executives and should be viewed as part of pay mix rather than a direct buy/sell signal. For retail investors, the key facts are the size of the award and the multi-year monthly vesting schedule; any investment implications depend on company performance and future insider actions (e.g., exercises or sales).